Kornimate/medical-research-clean huggingface dataset:
rehabilitation strategies for social participation in chronic stroke survivors

Conditions: Stroke; Chronic Phase of Disease

Summary: the goal of this clinical trial is to test a new rehabilitation program, combining acceptance and commitment therapy with strategy training (st+act) to help people resume social participation after stroke and live in the community. investigators will also compare the changes in social participation and psychological flexibility from baseline to follow-up at one-month after rehabilitation to see if participants who receive st+act report clinically meaningful improvements (cohen's d=0.2 or greater) compared to st alone. participants will: * complete testing to see if they are eligible for the study. if qualified, complete testing to understand how the stroke has affected their daily life * be randomized to receive either st+act or st alone rehabilitation program for 10 sessions at their home * repeat part of the tests at the end of the intervention and one month after

in april 2025, the investigators changed the recruitment status because the first enrolled participant ended up being ineligible. the investigators also updated eligibility criteria and outcome measures to be consistent with the irb protocol.

Eligibility criteria:
inclusion criteria: 1. primary diagnosis of chronic stroke, ≥6 months post onset, 2. ≥18 years old, 3. community-dwelling (i.e., living in a residential setting in the community), 4. restrictions in social participation, indicated by activity card sort (\<80% of pre-stroke activities) exclusion criteria: 1. progressive neurological diagnosis (e.g., dementia, parkinson's disease, multiple sclerosis, or brain tumor) reported by participants or proxy, 2. inability to provide written informed consent, 3. severe aphasia (score 0 or 1 on the boston diagnostic aphasia examination 3rd edition severity rating scale), 4. currently undergoing stroke rehabilitation or mental health intervention (but participation in maintenance sessions, self-help groups, or couples therapy is permitted), 5. major depressive disorder, indicated by prime-md, unless undergoing treatment for at least 4 weeks and are released to participate by their physician or counselor 6. bipolar or psychotic disorder, indicated by prime-md, or 7. substance abuse within 3 months, indicated by mini-international neuropsychiatric interview

Keywords: strategy training acceptance and commitment therapy social participation
prevention of clostridium difficile infections using lactobacillus plantarum 299v strain

Conditions: Clostridium Difficile

Summary: the aim of this study was to analyze whether the use of the lp299v strain reduces the risk of clostridium difficile infection (cdi) among patients receiving antibiotics and hospitalized in the nephrology and transplantation ward. patients from risk group (receiving immunosuppressive drugs and treated with antibiotics) were enrolled into study. participants will be divided into two groups. first group will receive one capsule of lactobacillus plantarum 299v (lp299v) orally per a day. second group will receive placebo.

clostridium difficile is currently the most frequently identified pathogen causing antibiotic-associated diarrhoea and the main cause of nosocomial diarrhoea. in regard to observed worldwide increase rate of infection and mortality from cdi the prevention of clostridium difficile infections seems to be crucial, especially in patients at cdi high risk. so far, it has not been unambiguously proven that probiotics are effective in the prevention of clostridium difficile infection among patients undergoing antibiotic therapy. the lactobacillus plantarum 299v (lp299v) is a gram-positive lactic acid bacteria that naturally occurs on the surface of human intestinal mucosa. specific properties to the gut mucosa colonization are due to mannose-dependent adhesion of lp299v to the epithelium of human intestines.this ability of lp299v leads to reduction of bacterial translocation from the intestinal lumen into the blood vessels, can prevent adhesion of many pathogens to intestinal epithelium and modulate the inflammatory response of the epithelium. the strain 299v of lactobacillus plantarum has been found to decrease the severity of gastrointestinal adverse effects during antibiotic therapy. limited data are available regarding the efficacy of lp299v for preventing clostridium difficile infections.

Eligibility criteria:
inclusion criteria: * over 18 years old * organ transplantation or receiving immunosuppressive drugs for any other reasons * antibiotics therapy exclusion criteria: * no consent to participate in the study

Keywords: clostridium difficile infection lactobacillus plantarum 299v organ transplantation antibiotic-associated diarrhoea
common sensing and right ventricular automatic capture (cognate)

Conditions: Bradycardia; Chronotropic Incompetence

Summary: this study will collect data on features for future pacemakers via an external non-implantable system.

cognate is an acute, confirmatory prospective, multi-center study designed to gather data on brady and crt-p indicated patients, with no restrictions on the type/brand of leads. this study will enroll up to 80 patients in up to 12 centers. total duration of the study is expected to be 9 months.

Eligibility criteria:
inclusion criteria: * patients who are scheduled to receive either pacemaker (dual chamber) or crt-p devices based on physician discretion * patients who are willing and capable of participating in all testing associated with this clinical investigation * patients who are age 18 or above, or of legal age to give informed consent specific to state and national law exclusion criteria: * patient enrolled in any concurrent study, without boston scientific crm written approval, that may confound the results of this study * patients with a prosthetic mechanical tricuspid heart valve * women who are pregnant

Keywords: bradycardia pacemaker
dermatological abnormalities in beta-thalassemia major

Conditions: Beta-Thalassemia

Summary: to study the frequency and pattern of dermatological abnormalities in egyptian childern with beta thalassemia.relationof abnormalities to duration of disease and frequency of transfusion

thalassemia refers to agroup of inherited disease characterized by decreased or absent synthesis of normal globin .skinvdisorders are usually neglected and frequently underdiagnosed among these patients.skin disease specially pruritus and xerosis are observed highly frequently in patients with beta-thalassemia.pityriasis alba is arelatively common skin disorder.the trophic skin changes and leg ulcers occurred after the age of 15 years

Eligibility criteria:
inclusio2n criteria: * clinical diagnosis of dermatological abnormalities in thalassemic patient. must be on chelator exclusion criteria: * patient with other hemolytic anemia. childern with any abnormalities prior to the diagnosis of thalassemi
nutrition-based interventions to prevent cognitive decline

Conditions: Cognitive Dysfunction; Cognition Disorder; Memory Disorders; Cognitive Impairment; Neurocognitive Disorders

Summary: this study intends to evaluate the feasibility and the effectiveness of an innovative and integrated nutrition-based intervention addressing key modifiable risk factors for dementia while meeting participants' preferences for nutrition-related sessions. the intervention will include lifestyle group sessions regarding nutrition education and physical activity, individualized nutrition-based cognitive training at home, as well as clinical nutrition consultations.

the present project is a randomized controlled trial (rct) to study the feasibility and effectiveness of a 6-month nutrition-based intervention designed to prevent cognitive decline in adults at higher risk of dementia. eligible individuals (n=120) recruited at primary health care centers or in the community will be randomized (1:1) into two arms: intervention and control groups. the intervention group will be invited to participate in nutrition-based sessions of 180-minutes per week, directed by a nutritionist, to improve participants' skills in preparing healthy meals and reduce sedentary behaviours. participants will also be asked to perform nutrition-based cognitive training at home and to attend individualized clinical nutrition consultations. the control group will participate in data assessment and will receive a healthy recipes cookbook to thank for their participation. they will also receive an invitation to participate in free healthy cooking workshops, which will be offered upon the completion of data collection. both groups will continue receiving the usual standard care in their healthcare unit. participants' assessments will be performed at baseline and will be repeated at the end of intervention (6 months after the beginning of the intervention). a follow-up assessment will be conducted 6 months after the intervention concludes. adherence outcomes, as well as lifestyle, health and anthropometric data, cognitive performance, subjective memory complaints, anxiety and depression, quality of life and self-reported physical activity will be evaluated.

Eligibility criteria:
inclusion criteria: * aged from 55 to 85 years old; * at least 4 years in the regular school system; * higher individual risk for dementia defined as a score ≥6 points on the cardiovascular risk factors, aging and dementia dementia risk score (caide). exclusion criteria: * montreal cognitive assessment (moca) score lower than the validated cutoff points defined as 2 standard deviations below the normative reference value for the corresponding age and education in the portuguese population; * having a medical condition limiting the participation in the intervention (e.g., blindness, amputation...); * lack of autonomy in daily activities; * diagnosis of dementia or major incapacity.

Keywords: healthy aging dementia cognitive dysfunction diet, food and nutrition diet, mediterranean randomized controlled trial
parkinson's disease registry

Conditions: Parkinson Disease

Summary: the purpose of the parkinson's disease registry (pdr) is to develop a nation-wide database of persons with parkinson's disease (pd) in taiwan.

among degenerative neurological disease, pd is the second most common disorder. although a wide range of incidence and prevalence rate exist in reviewed literatures due to a consequence of variation in study methodologies, the crude prevalence rate above 60 year-old is 1%. increase in aging population will lead to an increase in pd patients. the pdr will be used to facilitate the understanding of basic epidemiological features of the disease, genetic and non-genetic risk factors, co-morbidity, the up-to-date treatment strategies and the related economic burden from medical and surgical treatment (deep brain stimulation), to develop new therapeutic protocols as well as healthcare policies, and ultimately, to improve the quality of life of pd patients. pdr will also be served as data bank for investigators in the field of pd to quickly identify and notify research subjects about other research studies for which they are eligible. patient who registered can also sign their consent for a future brain donation after they passed away. methods: the 4 main tzu chi hospitals from hualien, da lin, taichung, and taipei will serve as representative of pilot study for national registry. this will be a record-based, multi-center, nation-wide, cohort study. a user-friendly, yet, encrypted registration platform will be provided through internet for authorized personnel. the contents of pdr will be as follow: demographic features, risk factors, clinical profiles of diagnostic criteria, co-morbidity, images profiles, treatment regimens in details, prognosis, health-related quality of life, and neuropsychological assessment batteries. expected results: 1. to facilitate the understanding of demographic epidemiological features of pd. 2. to find the risk factors of pd and the possible intervention toward disease prevention in taiwan. 3. to find the comorbidity of the disease, and the solution toward better treatment and related outcome. 4. assess current treatment approaches and develop best-practice guidelines. 5. tracking the health-related quality of life of pd patient as well as care-givers and the economic impact from different treatment regimens of best medications versus surgical interventions (neuromodulation / neuro-regeneration) from time to time. 6. drive the development of innovative research projects. 7. accelerate the process of informing patients of research projects for which they may be eligible. key words: parkinson's disease, registry, epidemiology, treatment, prognosis

Eligibility criteria:
inclusion criteria: * clinical diagnosis of parkinson's disease exclusion criteria: * none

Keywords: parkinson's disease, risk factors, epidemiology
study of two dosing schedules of adalimumab in subjects with moderate to severe chronic plaque psoriasis

Conditions: Psoriasis

Summary: study of two dosing schedules of adalimumab in subjects with moderate to severe chronic plaque psoriasis


Eligibility criteria:
inclusion criteria: * diagnosis of moderate to severe chronic plaque psoriasis * active psoriasis, despite topical therapies exclusion criteria: * other active skin diseases or skin infections * prior exposure to any anti-tnf therapy * subject has other active skin diseases * multiple concomitant therapy restrictions and/or washouts (topicals, uv, other systemic ps therapies) * poorly controlled medical conditions * history of neurologic symptoms suggestive of central nervous system (cns) demyelinating disease * history of cancer or lymphoproliferative disease * history of active tb or listeriosis, or persistent chronic or active infections * known to have immune deficiency or is immunocompromised * clinically significant abnormal laboratory test results * erythrodermic psoriasis or generalized pustular psoriasis
dumping syndrome after operation of esophageal atresia type iii

Conditions: Oesophageal Atresia; Dumping Syndrome

Summary: the purpose of this study is to evaluate the prevalence at 3.5 months of age of dumping syndrome in children operated at birth for oesophageal atresia type iii et iv.

consecutive patients with type iii and iv oesophageal atresia that are born in 8 different centers in france and sydney (australia) are included in the study, if willing. as soon as they weigh more than 4.150kg and if they are still younger than 3.5 months, an oral glucose tolerance test (ogtt) is performed. glycemia and insulinemia are monitored every 30 minutes from intake to 240 minutes. clinical signs that are presented are noted. if early hyperglycemia or late hypoglycemia are biologically or clinically observed, ascarbose treatment is initiated.

Eligibility criteria:
inclusion criteria: * new born less than 3.5 months or age corrected for premature new born * weight ≥ 4, 150 kg * esophageal atresia (ea) type iii or iv * ea surgery between may 2013 and june 2016 * stop of prokinetic treatment \> 72 h before ogtt * information and consent of parents * patients with health insurance exclusion criteria: * age \> 3.5 months * weight \< 4.150 kg * other types of ea * dumping syndrom from other origin: microgastria, dysautonomia, small intestine surgery * other pathology that can modify glycemia: neonatal diabete, hyperinsulinism * treatment that can modify gastric motility: domperidone, erythromycin, baclofen that hasn't been stopped in the 72h before ogtt * absence of consent * patient judiciary protected * simultaneous participation to another clinical trial * no health insurance

Keywords: infants oesophageal atresia dumping syndrome prevalence type iii and iv oral glucose tolerance test early hyperglycemia late hypoglycemia
imipenem in critically ill patients

Conditions: Critically Ill Patients With ECMO

Summary: extracorporeal membrane oxygenation (ecmo) has become increasingly used for lifesaving respiratory and/or cardiac failure support in critically ill patients, including those with life-threatening severe infections. this cardiopulmonary bypass device has been shown to enhance the profound pathophysiological changes in this patient population, resulting in an alteration of the pharmacokinetics (pk) of antimicrobial agents. the aim of this study was to determine the effect of ecmo on the pk of imipenem in critically ill patients supported by this cardiopulmonary bypass device. methods the study was conducted in critically ill patients with respiratory and/or cardiac failure and suspected severe nosocomial infections who were supported by ecmo. all patients received a 1-h infusion of 0.5 g of imipenem every 6 h and imipenem pk studies were carried out on the fourth dose of drug administration.


Eligibility criteria:
inclusion criteria: * patient age \>18 year * patients who diagnosed as severe sepsis * admitted into the icu * supported with ecmo exclusion criteria: * patients who pregnant * patients who have documented hypersensitivity to carbapenem

Keywords: pharmacokinetic imipenem extracorporeal membrane oxygenation
topical anaesthesia in cutaneous head and neck surgery

Conditions: Pain, Acute; Head and Neck Cancer; Cutaneous Tumor

Summary: this study aims to assess if emla or ethyl chloride spray are effective in reducing the pain associated with local anaesthetic administration in cutaneous surgery of the head and neck compared to a placebo and control group through a randomized control trial study design.

operations on cutaneous tissues of the head and neck are some of the most frequently performed types of operation performed. they can often successfully be performed using local anaesthetic (la). however, tissues in this anatomic area are some of most sensitive tissues in the body to nociceptive pain. as such, local anaesthetic can be a distressing experience for patients in many ways. unfortunately, it is also the most common anatomical site for cutaneous malignancies. the majority of these lesions are resected under local anaesthetic. however, one of the major disadvantages of local anaesthetic such as lidocaine is pain during administration. several interventions have been used to reduce pain from needles and injections including ethylene chloride cryoanalgesic spray and topical anaesthetic agents including emla (lidocaine and prilocaine) and ametop ointments. these have been extensively used in paediatric populations with great success to reduce pain during procedures requiring hypodermics such as cannulation. several studies have trialled these interventions in adult populations across a variety of anatomical locations with variable results. the investigators aim to assess the efficacy of emla and ethyl chloride in mitigating nociceptive pain associated with local anaesthetic administration in patients undergoing cutaneous head and neck surgery.

Eligibility criteria:
inclusion criteria: * aged at least 18 years * receiving surgery to cutaneous tissues of the head and neck * procedure performed under local anaesthetic exclusion criteria: * paediatric patients * surgery performed under general anaesthetic * mucosal operative site (e.g. oral cavity) * significant cognitive impairment (e.g. severe dementia) * known sensitivity/allergy to emla * history of a pain disorder (e.g. complex regional pain syndrome).
the evaluation of tci378 and tci507 probiotics on weight-lowering efficacy in adults

Conditions: Weight Loss

Summary: to assess the evaluation of tci378 and tci507 probiotics on weight-lowering efficacy in adults

this is a double-blind and randomized study. subjects are informed to consume the samples every day for 2 months. the person who is evaluated as overweight by the doctor will be invited to participate in this trial. the efficacy assessment items and questionnaires are collected at every visit of the trial.

Eligibility criteria:
inclusion criteria: 1. adults between the ages of 20 and 65 who are willing to sign the consent form of the subject. 2. bmi ≥ 24 or male body fat ≥ 25%, female body fat ≥ 30%. 3. those who are not pregnant and are willing to cooperate with contraception during the trial period. 4. no history of cardiovascular disease, history of organ transplantation, history of epilepsy or convulsions, liver and kidney disease, malignant tumor, endocrine disease, mental disease, alcohol or drug abuse, or other major organic diseases (according to medical history). exclusion criteria: 1. pregnant women, people with a history of cardiovascular disease, organ transplantation, epilepsy or convulsions, liver and kidney disease, malignant tumors, endocrine diseases, mental diseases, alcohol or drug abuse, and other major organic diseases (according to medical history). 2. no person who has undergone major surgery or bariatric surgery (according to medical history). 3. drugs that affect body fat, waist circumference, or significantly increase weight, such as systemic corticosteroids, tricyclic antidepressants, atypical psychiatric drugs, and mood stability, have been used at present or within 3 months before participating in the screening drugs (according to medical history).
anti-cd19 car-t cells for relapsed or refractory acute lymphoblastic leukemia and lymphomas

Conditions: Acute Lymphoblastic Leukemia ,Lymphomas

Summary: this is a single arm, open-label, single center study to determine the safety and efficacy of anti-cd19 car-t cells in patients with relapsed or refractory acute lymphoblastic leukemia and lymphomas.

cd19 has been extensively evaluated as a therapeutic target for relapsed or refractory b cell malignancy by chimeric antigen receptor t cell therapy,this is a single arm, open-label, single center study to determine the safety and efficacy of anti-cd19 car-t cells in patients with refractory acute lymphoblastic leukemia and lymphomas.

Eligibility criteria:
inclusion criteria: subjects diagnosed as relapsed or refractory acute lymphoblastic leukemia and lymphomas ，and have no effective treatment option (such as autograft or allogeneic stem cell transplantation) and estimated survival time of the current treatment \< 2 years, the specific requirements are as follows: 1. male or female aged 18-70 years old ; 2. estimated survival time \> 12 weeks; 3. relapsed and refractory acute lymphoblastic leukemia and lymphoma were confirmed by physical examination, pathological examination, laboratory examination and imaging; 4. chemotherapy failure or recurrent acute lymphoblastic leukemia and lymphomas; 5. glutamic-pyruvic transaminase, glutamic oxalacetic transaminase\< 3 fold of normal level; 6. bilirubin\<2.0mg/dl; 7. karnofsky performance status\>50% at the time of screening; 8. adequate pulmonary, renal, hepatic, and cardiac function; 9. fail in autologous or allogenic haemopoietic stem cell transplantation; 10. not suitable for stem cell transplantation conditions or abandoned due to conditions; 11. free of leukocytes removal contraindications; 12. voluntarily join car-t clinical trial ,understand and sign written informed consent. exclusion criteria: 1. the patient is a pregnant or breastfeeding woman, or is a woman with a pregnancy plan within six months; 2. patients have infectious diseases (such as hiv, active tuberculosis, etc.); 3. the patient is an active hepatitis b or hepatitis c infection; 4. feasibility assessment proves that the efficiency of transduction of lymphocyte is below 10% or the lymphocyte cannot be propagated ; 5. abnormal vital signs; 6. subjects with mental or psychological illness who cannot be combined with treatment and efficacy evaluation; 7. highly allergic constitution or history of severe allergies, especially allergy to interleukin-2; 8. general infection or local severe infection, or other infection that is not controlled; 9. dysfunction in lung, heart, kidney and brain; 10. severe autoimmune diseases; 11. other symptoms that are not applicable for car-t.

Keywords: acute lymphoblastic leukemia ;lymphomas